GlaxoSmithKline plc (NYSE:GSK) Stock Position Increased by Pinkerton Retirement Specialists LLC

Pinkerton Retirement Specialists LLC lifted its position in GlaxoSmithKline plc (NYSE:GSK) by 3.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,944 shares of the pharmaceutical company’s stock after buying an additional 1,672 shares during the period. Pinkerton Retirement Specialists LLC’s holdings in GlaxoSmithKline were worth $2,239,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. D Orazio & Associates Inc. raised its stake in shares of GlaxoSmithKline by 200.0% in the 1st quarter. D Orazio & Associates Inc. now owns 600 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 400 shares in the last quarter. Berman Capital Advisors LLC raised its stake in shares of GlaxoSmithKline by 58.1% in the 2nd quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 241 shares in the last quarter. Financial Gravity Wealth Inc. raised its stake in shares of GlaxoSmithKline by 62.7% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 308 shares in the last quarter. Reilly Financial Advisors LLC raised its stake in shares of GlaxoSmithKline by 36.7% in the 1st quarter. Reilly Financial Advisors LLC now owns 950 shares of the pharmaceutical company’s stock worth $36,000 after buying an additional 255 shares in the last quarter. Finally, Princeton Global Asset Management LLC bought a new stake in shares of GlaxoSmithKline in the 1st quarter worth $37,000. 11.30% of the stock is currently owned by institutional investors.

In related news, Director Plc Glaxosmithkline bought 385,714 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were bought at an average cost of $14.00 per share, with a total value of $5,399,996.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.00% of the stock is owned by insiders.

Shares of GlaxoSmithKline stock traded up $0.47 on Friday, reaching $41.45. 1,382,191 shares of the company were exchanged, compared to its average volume of 2,410,493. The stock has a fifty day moving average price of $40.89 and a 200-day moving average price of $40.49. The firm has a market capitalization of $101.65 billion, a price-to-earnings ratio of 13.12, a price-to-earnings-growth ratio of 1.96 and a beta of 0.71. The company has a current ratio of 0.71, a quick ratio of 0.48 and a debt-to-equity ratio of 7.86. GlaxoSmithKline plc has a fifty-two week low of $36.41 and a fifty-two week high of $42.47.

GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. The company had revenue of $10.04 billion for the quarter, compared to analyst estimates of $9.55 billion. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. On average, equities analysts anticipate that GlaxoSmithKline plc will post 2.91 earnings per share for the current fiscal year.

A number of brokerages have recently issued reports on GSK. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Thursday, April 25th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, August 13th. Cowen reaffirmed a “hold” rating and set a $45.00 target price on shares of GlaxoSmithKline in a research report on Monday, June 10th. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of GlaxoSmithKline in a research report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and two have given a buy rating to the company. GlaxoSmithKline currently has a consensus rating of “Hold” and an average target price of $41.79.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: Why do analysts give a neutral rating?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.